703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)

BACKGROUND: Lefamulin (LEF), a novel pleuromutilin protein synthesis inhibitor in development for use as an empiric IV and oral monotherapy for CABP, recently demonstrated safety and efficacy in two phase 3 trials in adults with CABP (PORT II–V). LEF IV or IV/oral (5–7 days; 10 days for methicillin-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Paukner, Susanne, Arends, S J Ryan, Gelone, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811268/
http://dx.doi.org/10.1093/ofid/ofz360.771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811268/
http://dx.doi.org/10.1093/ofid/ofz360.771

Ejemplares similares